BeyondSpring is trading at $0.82, up 6.23% in after-hours trading, with no newly identified company-specific announcement on September 30.
- September 29 news reported FDA Fast Track designation for plinabulin plus docetaxel and a Biolin transaction supporting China-based DUBLIN-4 trial activity.
- That prior news may provide context, but available reporting does not establish it as the direct cause of the after-hours rise.
- No volume details were provided in the supplied price context.